Exploring a new tumor suppressor to reduce breast cancer disparities in African American women.
Official title: SELENOF is a Novel Tumor Suppressor and a New Target to Overcome Racial Disparity in Breast Cancer.
Funded at Loyola University Chicago · NIH-10927355 · Data updated 2026-11-12
This study is looking at a protein called SELENOF that helps fight breast cancer, especially in African American patients, to see how its lower levels might lead to higher death rates from the disease, with the goal of finding ways to boost this protein and improve treatment outcomes for those affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Loyola University Chicago NIH-funded |
| Lab location | 1 site (Maywood, United States) |
| Project start | September 11, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $429,652 |
| NIH project number | 5R01CA276482-02 |
| Project ID | NIH-10927355 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are African American women diagnosed with breast cancer, particularly those with lower levels of the SELENOF protein.
✕Less likely to help
Patients who are not African American or those with breast cancer unrelated to SELENOF levels may not benefit from this research.
What this research studies
This research investigates the role of a protein called SELENOF, which has been identified as a tumor suppressor in breast cancer. The study aims to understand how lower levels of SELENOF in African American patients contribute to higher breast cancer mortality rates. By examining genetic variations and protein expression in breast tumors, the researchers will develop therapeutic strategies to enhance SELENOF levels and improve patient outcomes. This approach includes laboratory experiments and potential clinical applications to address the racial disparities in breast cancer.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve survival rates for African American women with breast cancer.
How similar studies have gone: Previous research has shown promising results in targeting tumor suppressors to improve cancer treatment outcomes, suggesting that this approach may be effective.
Where this research is happening
-
Loyola University Chicago
Maywood, United States Active
Researchers
- Principal investigator: Kastrati, Irida — Loyola University Chicago
- Study coordinator: Kastrati, Irida
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.